Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Pharmacol Ther. 2016 Sep 6;168:126–142. doi: 10.1016/j.pharmthera.2016.09.012

Figure 2. AF-selective Pharmacology and Atrial-specific K currents.

Figure 2

(a) To maximize efficacy and safety an AF-selective drug should exhibit potent effects in atrial tissue at high rates (during fibrillation) without impacting ventricular AP and nSR. To achieve this, drugs could target channels that are predominantly expressed in atria vs. ventricles, shown in (b), or take advantage of atrioventricular differences in membrane potential and/or ion channel gating, as discussed here for Na channel blockers. (b) Ventricular (left) and atrial (right) APs and K currents underlying repolarization.